companies / enalare-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 2,499,1182.5M | ○ |
|---|---|---|
| founded | null | |
| hq | PRINCETON, New Jersey | |
| industry | unknown | |
| stage | null |
Enalare Therapeutics is developing ENA-001, a patent-protected breathing stimulant for acute respiratory depression. Target indications include opioid-overdose respiratory depression, post-operative respiratory compromise, and apnea of prematurity in infants. The new chemical entity is positioned to provide a non-opioid pharmacologic option for emergency and inpatient settings.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-01-01 | grant | 2,499,1182.5M | null | ○ |
WordPress 7.0, Apache HTTP Server 2.4.41, Yoast SEO 27.6, Ubuntu, Google Tag Manager, Google Tag Manager for WordPress 1.22.3, Slider Revolution, jQuery Migrate 3.4.1, PHP, Contact Form 7 6.1.6, MySQL, apache 2.4.41
| fact | status | src |
|---|---|---|
| Grant, $2.5M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |